Bhavesh D Kevadiya1, Brendan M Ottemann1, Midhun Ben Thomas1, Insiya Mukadam2, Saumya Nigam1, JoEllyn McMillan1, Santhi Gorantla1, Tatiana K Bronich2, Benson Edagwa1, Howard E Gendelman3. 1. Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA. 2. Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA. 3. Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: hegendel@unmc.edu.
Abstract
The discipline of neurotheranostics was forged to improve diagnostic and therapeutic clinical outcomes for neurological disorders. Research was facilitated, in largest measure, by the creation of pharmacologically effective multimodal pharmaceutical formulations. Deployment of neurotheranostic agents could revolutionize staging and improve nervous system disease therapeutic outcomes. However, obstacles in formulation design, drug loading and payload delivery still remain. These will certainly be aided by multidisciplinary basic research and clinical teams with pharmacology, nanotechnology, neuroscience and pharmaceutic expertise. When successful the end results will provide "optimal" therapeutic delivery platforms. The current report reviews an extensive body of knowledge of the natural history, epidemiology, pathogenesis and therapeutics of neurologic disease with an eye on how, when and under what circumstances neurotheranostics will soon be used as personalized medicines for a broad range of neurodegenerative, neuroinflammatory and neuroinfectious diseases.
The discipline of neurotheranostics was forged to improve diagnostic and therapeutic clinical outcomes for neurological disorders. Research was facilitated, in largest measure, by the creation of pharmacologically effective multimodal pharmaceutical formulations. Deploypan class="Species">ment of neurotheranostic agents could revolutionize staging and improve nervous system disease therapeutic outcomes. However, obstacles in formulation design, drug loading and payload delivery still remain. These will certainly be aided by multidisciplinary basic research and clinical teams with pharmacology, nanotechnology, neuroscience and pharmaceutic expertise. When successful the end results will provide "optimal" therapeutic delivery platforms. The current report reviews an extensive body of knowledge of the natural history, epidemiology, pathogenesis and therapeutics of neurologic disease with an eye on how, when and under what circumstances neurotheranostics will soon be used as personalized medicines for a broad range of neurodegenerative, neuroinflammatory and neuroinfectious diseases.
Authors: M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum Journal: Science Date: 1997-06-27 Impact factor: 47.728
Authors: Jasbir Singh; Michael Salcius; Shin-Wu Liu; Bart L Staker; Rama Mishra; John Thurmond; Gregory Michaud; Dawn R Mattoon; John Printen; Jeffery Christensen; Jon Mar Bjornsson; Brian A Pollok; Megerditch Kiledjian; Lance Stewart; Jill Jarecki; Mark E Gurney Journal: ACS Chem Biol Date: 2008-11-21 Impact factor: 5.100
Authors: Brendan M Ottemann; Austin J Helmink; Wenting Zhang; Insiya Mukadam; Christopher Woldstad; James R Hilaire; Yutong Liu; JoEllyn M McMillan; Benson J Edagwa; R Lee Mosley; Jered C Garrison; Bhavesh D Kevadiya; Howard E Gendelman Journal: Biomaterials Date: 2018-09-14 Impact factor: 12.479
Authors: Gizem Rüya Topal; Mária Mészáros; Gergő Porkoláb; Anikó Szecskó; Tamás Ferenc Polgár; László Siklós; Mária A Deli; Szilvia Veszelka; Asuman Bozkir Journal: Pharmaceutics Date: 2020-12-29 Impact factor: 6.321